Waters Corporation Expands Its Biological Analysis Portfolio with Halo Labs Acquisition

Waters Corporation, a global leader in analytical instruments, has made a significant move by acquiring Halo Labs™, a company specializing in innovative imaging technology. This strategic acquisition aims to bolster Waters' portfolio in the biological analysis sector, particularly as it relates to therapeutic products such as cell and gene therapies.

Halo Labs is renowned for its advanced Aura™ platform, which utilizes distinct particle analysis technology. This platform complements Waters’ existing solutions from the Wyatt Technology™ line, enabling comprehensive analysis of subvisible particles—something conventional methods often overlook. This capability is especially crucial in areas like CAR-T cell therapy, where identifying and quantifying particulate contaminants can be vital for product safety and efficacy.

Enhancing Therapeutic Development

According to Dr. Udit Batra, the President and CEO of Waters Corporation, this acquisition is aimed at integrating Halo Labs' cutting-edge technology into the development cycle of new and existing biopharmaceutical molecules as well as enhancing quality control (QA/QC) processes. The addition of Halo’s high-performance, low sample volume technology allows for a wider array of sample types and volumes, provides earlier insights during therapeutic development, and boosts manufacturing safety.

"With the rapid growth seen in CAR-T therapies and the pressing need for innovative solutions, we're making meaningful investments in technologies our customers require. This acquisition not only fortifies our position in specialized analytical technologies but also aligns with our goal of supporting the emerging biopharmaceutical market," stated Dr. Batra.

Commitment to Quality and Progress

Rick Gordon, CEO of Halo Labs, expressed enthusiasm about the partnership, stating, "Joining forces with Waters, a company that shares our commitment to purposeful innovation and customer focus, amplifies our vision to expand our platform's capabilities. This merger is set to enhance the development and production of life-saving therapies while upholding our dedication to drug safety and quality. We are keen to facilitate groundbreaking advancements that will benefit patients globally."

The acquisition of Halo Labs is expected to have a negligible impact on Waters Corporation’s financial results within the next year, indicating a confidence in sustainable integration and long-term growth potential.

About Halo Labs

Halo Labs is a venture-backed company that specializes in scientific instrumentation and consumables. They offer high-performance tools for assessing formulation, stability, and quality control of biopharmaceutical products. By utilizing cutting-edge optical technology and imaging techniques, Halo Labs provides unrivaled insights for biopharmaceutical companies worldwide.

About Waters Corporation

Waters Corporation, listed on NYSE under the ticker WAT, boasts over 65 years of experience in developing analytical instruments, separation technologies, and software solutions. Their contributions are crucial in ensuring medication efficacy, food safety, and water purity, alongside maintaining the quality and sustainability of everyday products. With over 7,600 dedicated employees in more than 100 countries, Waters collaborates with clients across laboratories, manufacturing facilities, and hospitals to leverage the advantages of pioneering science.

In conclusion, the acquisition of Halo Labs by Waters Corporation not only enhances their capabilities in the market for advanced therapeutic analysis but also underscores their commitment to delivering innovative and safe healthcare solutions. As the demand for powerful biotherapeutics continues to grow, Waters is poised to lead the charge in providing the analytical technologies necessary to ensure these therapies meet the highest standards of quality and safety.